All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the AML Global Portal was delighted to speak to Jane Churpek, The University of Wisconsin, Madison, US. We discussed, how close we are to implementing germline precision medicine in acute myeloid leukemia.
In recent years, researchers started to look at how many patients who develop myeloid diseases have a germline predisposition and what is the impacts of these mutations on patient prognosis.
How close are we to implementing germline precision medicine in acute myeloid leukemia?
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox